<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054140</url>
  </required_header>
  <id_info>
    <org_study_id>P2-IMU-838-PMS</org_study_id>
    <nct_id>NCT05054140</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis</brief_title>
  <acronym>CALLIPER</acronym>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunic AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunic AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety,&#xD;
      and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multicenter, randomized, double-blind, placebo-controlled study with a&#xD;
      blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy,&#xD;
      safety, and tolerability of IMU838 in adult patients with PMS. The study will consist of the&#xD;
      following periods:&#xD;
&#xD;
      Screening Period: Approximately 28 days Main Treatment Period: Up to 120 weeks (approximately&#xD;
      2 years) Open Label Extension Period: Up to approximately 8 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">July 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of IMU-838 versus placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Annualized rate of percent brain volume change (PBVC) during MT period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy IMU-838 versus placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to 24-week confirmed disability progression based on expanded disability status scale (EDSS) during the MT period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety IMU-838 versus placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events (AEs) and serious AEs (SAEs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>IMU-838</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMU-838 as tablet; Administration: Oral - daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo as tablet; Administration: Oral - daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMU-838</intervention_name>
    <description>IMU-838 tablets</description>
    <arm_group_label>IMU-838</arm_group_label>
    <other_name>Vidofludimus calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching IMU-838</intervention_name>
    <description>Placebo matching IMU-838 tablets</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, age 18 to 65 years (inclusive).&#xD;
&#xD;
          -  EDSS score at screening between 3.0 to 6.5 (both inclusive)&#xD;
&#xD;
          -  No evidence of relapse in the last 24 months before randomization, AND Patients&#xD;
             diagnosed according to 2017 revised McDonald Criteria 1 and the 2013 revised&#xD;
             classification of disease courses 2 as either&#xD;
&#xD;
               1. SPMS inpatients showing evidence of Gd+MRI lesions (active SPMS) or without&#xD;
                  Gd+MRI lesions (non-active SPMS) in the last 12 months, OR&#xD;
&#xD;
               2. PPMS&#xD;
&#xD;
          -  Willingness and ability to comply with the protocol.&#xD;
&#xD;
          -  Written informed consent given by the patient before the beginning of any&#xD;
             study-related procedure.&#xD;
&#xD;
          -  Documented evidence of disability progression not temporarily related to a relapse in&#xD;
             the last 24 months before randomization, adjudicated by a central independent reviewer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease other than MS that may better explain the signs and symptoms, including a&#xD;
             history of complete transverse myelitis.&#xD;
&#xD;
          -  Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica&#xD;
             (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-associated&#xD;
             encephalomyelitis (i.e.,presence of anti-NMO [aquaporin-4] antibodies or anti-MOG&#xD;
             antibodies).&#xD;
&#xD;
          -  Previous or current use of MS treatments lifelong, or within a pre-specified time&#xD;
             period.&#xD;
&#xD;
          -  Use of any investigational product within 8 weeks or 5 the respective PK half- life&#xD;
             before the date of informed consent, whichever is longer, and throughout the study.For&#xD;
             some investigational products, prolonged biological effects beyond 8 weeks should be&#xD;
             considered.&#xD;
&#xD;
          -  Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2)&#xD;
             within14 days before randomization. In case of known SARS-CoV-2 infection, patients&#xD;
             should be randomized no earlier than 14 days after 2 consecutive negative tests&#xD;
             confirming virus negative status.The screening period can be extended for these&#xD;
             patients to accommodate the required virus negativity.&#xD;
&#xD;
          -  Positive IFN-gamma release assay (IGRA) for Mycobacterium tuberculosis at SV1.&#xD;
&#xD;
          -  Positive hepatitis B virus (HBV) surface antigen, hepatitis B core antibody, positive&#xD;
             hepatitis C virus (HCV) antibody, and/or HIV-antigen-antibody test at SV1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. F., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cleveland Ohio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Muehler, MD</last_name>
    <phone>+49 89 2080 477 00</phone>
    <email>info@imux.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Ukraine</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>76493</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

